RxDoctor Payments Data

Joseph Vassalotti, MD

Nephrology · New York, NYNPI 1689692311

Payments from drug & device makers

$50,149in general payments, 2019–2025

Across 22 payments — averaging $2279.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Renalytix AI, Inc.$17K
  • Janssen Scientific Affairs, LLC$15K
  • Novo Nordisk$11K
  • AstraZeneca$5K
  • Eli Lilly$3K
  • Sanofi$127
  • plus $185 from 3 others

What the payments were for

  • Consulting fees$29,10882%
  • Speaking & faculty fees$4,00011%
  • Travel & lodging$1,6555%
  • Food & beverage$7902%
  • Education$960%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,149 in reported general payments places this provider in the 85th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$85,743
Medicare patients
245
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone35$51,129
JardianceEmpagliflozin48$49,789
FarxigaDapagliflozin Propanediol31$46,009
VeltassaPatiromer Calcium Sorbitex31$34,046
LokelmaSodium Zirconium Cyclosilicate20$23,650
EntrestoSacubitril/Valsartan12$7,648
Candesartan Cilexetil24$2,026
Losartan Potassium92$960
Potassium Citrate ErPotassium Citrate16$884
Sodium Polystyrene Sulfonate20$839
Famotidine20$449
Atorvastatin Calcium43$397
Amlodipine Besylate41$334
Olmesartan Medoxomil27$316
Metoprolol Succinate31$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$5,167$69,65951 claims
BayerKerendia$29$51,12935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 nephrology providers in New York.

Other nephrology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →